IDEAYA Biosciences, Inc. (IDYA) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $31.81 (-3.28%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 6, 2026 | Gregory Renza | Truist Financial | $60.00 | +88.6% |
| Sep 9, 2025 | Gregory Renza | RBC Capital | $38.00 | +19.5% |
| Sep 8, 2025 | Matthew Biegler | Oppenheimer | $36.00 | +13.2% |
| Sep 4, 2025 | lvan Tuerkcan | JMP Securities | $41.00 | +28.9% |
| Nov 5, 2024 | Andrew Berens | Leerink Partners | $27.00 | -15.1% |
| Oct 24, 2024 | David Dai | UBS | $50.00 | +57.2% |
| Sep 25, 2024 | Graig Suvannavejh | Mizuho Securities | $55.00 | +72.9% |
| Sep 23, 2024 | Corinne Jenkins | Goldman Sachs | $48.00 | +50.9% |
| Sep 23, 2024 | Ben Burnett | Stifel Nicolaus | $66.00 | +107.5% |
| Sep 23, 2024 | Justin Zelin | BTIG | $62.00 | +94.9% |
| Sep 10, 2024 | Ben Burnett | Stifel Nicolaus | $68.00 | +113.8% |
| Aug 27, 2024 | Yigal Nochomovitz | Citigroup | $58.00 | +82.3% |
| Aug 7, 2024 | Matthew Biegler | Oppenheimer | $53.00 | +66.6% |
| Jul 10, 2024 | Gregory Renza | RBC Capital | $61.00 | +91.8% |
| Jul 8, 2024 | Graig Suvannavejh | Mizuho Securities | $50.00 | +57.2% |
| Jun 3, 2024 | Ben Burnett | Stifel Nicolaus | $63.00 | +98.1% |
Top Analysts Covering IDYA
IDYA vs Sector & Market
| Metric | IDYA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 9 | 8 | 19 |
| Target Upside | +71.0% | +153002.0% | +21.5% |
| P/E Ratio | -22.63 | 3.49 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $17M | $17M | $17M | 7 |
| 2027-03-31 | $21M | $21M | $21M | 4 |
| 2027-06-30 | $27M | $27M | $27M | 6 |
| 2027-09-30 | $34M | $34M | $34M | 4 |
| 2027-12-31 | $54M | $54M | $54M | 7 |
| 2028-12-31 | $278M | $278M | $278M | 12 |
| 2029-12-31 | $159M | $600M | $1.10B | 11 |
| 2030-12-31 | $275M | $1.03B | $1.91B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.96 | $-0.96 | $-0.96 | 7 |
| 2027-03-31 | $-0.91 | $-0.91 | $-0.91 | 3 |
| 2027-06-30 | $-0.87 | $-0.87 | $-0.87 | 3 |
| 2027-09-30 | $-0.83 | $-0.83 | $-0.83 | 4 |
| 2027-12-31 | $-0.67 | $-0.67 | $-0.67 | 3 |
| 2028-12-31 | $-3.99 | $-2.46 | $0.31 | 10 |
| 2029-12-31 | $-0.88 | $-0.42 | $-0.02 | 4 |
| 2030-12-31 | $0.11 | $2.38 | $4.99 | 4 |
Frequently Asked Questions
What is the analyst consensus for IDYA?
The consensus among 9 analysts covering IDEAYA Biosciences, Inc. (IDYA) is Buy with an average price target of $57.00.
What is the highest price target for IDYA?
The highest price target for IDYA is $68.00, set by Ben Burnett at Stifel Nicolaus on 2024-09-10.
What is the lowest price target for IDYA?
The lowest price target for IDYA is $27.00, set by Andrew Berens at Leerink Partners on 2024-11-05.
How many analysts cover IDYA?
9 analysts have issued ratings for IDEAYA Biosciences, Inc. in the past 12 months.
Is IDYA a buy or sell right now?
Based on 9 analyst ratings, IDYA has a consensus rating of Buy (2.00/5) with a +71.0% upside to the consensus target of $57.00.
What are the earnings estimates for IDYA?
Analysts estimate IDYA will report EPS of $-0.96 for the period ending 2026-12-31, with revenue estimated at $17M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.